Latest Healthcare News

Page 108 of 198
IMEXHS Limited reported a $3 million net loss for the half-year ending June 2025, driven by a significant goodwill impairment, while annualised recurring revenue rose 11%. The company completed a $2.6 million capital raise to support growth amid ongoing cost optimisation and automation efforts.
Ada Torres
Ada Torres
29 Aug 2025
Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.
Ada Torres
Ada Torres
29 Aug 2025
Resonance Health Limited reported a 29% revenue increase to $11.07 million for FY25 but posted a net loss of $1.73 million, reflecting strategic investments and expansion in clinical trial services.
Ada Torres
Ada Torres
29 Aug 2025
MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.
Ada Torres
Ada Torres
29 Aug 2025
Alterity Therapeutics reported a reduced net loss of A$12.15 million for FY2025, buoyed by positive Phase 2 clinical trial results for its lead drug ATH434 in Multiple System Atrophy and a successful A$40 million capital raising.
Ada Torres
Ada Torres
29 Aug 2025
MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.
Ada Torres
Ada Torres
29 Aug 2025
4DMedical reports a robust 56% revenue increase in FY2025, driven by SaaS expansion and strategic partnerships, while advancing FDA clearance for its innovative CT – VQ™ lung imaging software.
Ada Torres
Ada Torres
29 Aug 2025
BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.
Ada Torres
Ada Torres
29 Aug 2025
4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.
Ada Torres
Ada Torres
29 Aug 2025
Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.
Ada Torres
Ada Torres
29 Aug 2025
Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.
Ada Torres
Ada Torres
29 Aug 2025
Immutep Limited reported a widened loss of A$61.4 million for FY2025, driven by increased R&D and clinical trial expenses, while progressing its lead immunotherapy candidate into a pivotal Phase III lung cancer trial. The company maintains a robust cash position supporting operations through 2026.
Ada Torres
Ada Torres
29 Aug 2025